Sacu-V 50 Tablet consists of two active ingredients:
Sacubitril (24 mg): This component is a prodrug that is metabolised into LBQ657, an inhibitor of an enzyme called neprilysin. Neprilysin is responsible for breaking down several vasoactive substances, including natriuretic peptides and bradykinin. By inhibiting neprilysin, sacubitril elevates the levels of these peptides, enhancing their beneficial effects on cardiovascular and renal health.
Valsartan (26 mg): As an angiotensin II receptor blocker (ARB), valsartan impedes the actions of angiotensin II on the AT1 receptor. This action reduces vasoconstriction, sodium and water retention, cardiac hypertrophy, and fibrosis.
Together, these ingredients result in vasodilation, decreased sodium and water retention, reduced cardiac workload, and inhibited cardiac remodelling. These combined effects contribute to improved cardiac function and reduced hospitalisation and mortality rates among heart failure patients.